A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer

Trial Profile

A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs LY 3009120 (Primary)
  • Indications Cancer metastases; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Tumours
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly
  • Most Recent Events

    • 21 Jul 2017 Planned End Date changed from 7 Jul 2017 to 1 Nov 2017.
    • 02 Jun 2017 Results (n=34; data cut off: 2 Jan 2016) assessing safety and tolerabilty presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 20 Jan 2017 Planned End Date changed from 1 Jan 2017 to 7 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top